{"id":"NCT04839354","sponsor":"Claudia R. Morris","briefTitle":"Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial","officialTitle":"Sickle Cell Disease Treatment With Arginine Therapy (STArT) Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-06-21","primaryCompletion":"2024-07-11","completion":"2024-07-11","firstPosted":"2021-04-09","resultsPosted":"2025-07-30","lastUpdate":"2025-07-30"},"enrollment":271,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Sickle Cell Disease"],"interventions":[{"type":"DRUG","name":"L-Arginine Hydrochloride","otherNames":[]},{"type":"OTHER","name":"Normal saline","otherNames":[]}],"arms":[{"label":"L-Arginine Hydrochloride","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The trial is designed to test intravenous (IV) arginine therapy in children with sickle cell disease (SCD) and vaso-occlusive painful episodes (VOE) to further knowledge on efficacy and safety of this orphan drug.","primaryOutcome":{"measure":"Time-to-crisis Resolution","timeFrame":"From study drug delivery to last IV opioid treatment (up to 1,724.1 hours)","effectByArm":[{"arm":"L-Arginine Hydrochloride","deltaMin":81.5,"sd":79.6},{"arm":"Placebo","deltaMin":88.6,"sd":152.2}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":["38527291","35426778","34724240","32384147","33075179","15998894","23645695","37064309","33815929","12626350","37587492","38775255"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":22,"n":129},"commonTop":["Nausea","Pyrexia","Headache","Vomiting","Acute chest syndrome"]}}